ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 1, 2010

Study Completion Date

March 30, 2015

Conditions
Disseminated NeuroblastomaRecurrent Neuroblastoma
Interventions
DRUG

ABT-751

Given orally

PROCEDURE

quality-of-life assessment

Ancillary studies

Trial Locations (12)

10032

Columbia University Medical Center, New York

19104

Children's Hospital of Philadelphia, Philadelphia

35294

University of Alabama at Birmingham, Birmingham

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48109

C S Mott Children's Hospital, Ann Arbor

63110

Washington University School of Medicine, St Louis

76104

Cook Children's Medical Center, Fort Worth

97239

Oregon Health and Science University, Portland

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

02115

Dana-Farber Cancer Institute, Boston

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT00436852 - ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment | Biotech Hunter | Biotech Hunter